NEXEL receives U.S. FDA acceptance of letter of intent for iPSC-derived cardiomyocyte platform ‘Cardiosight-S’
Nexel Leads the FDA Roadmap: Secures Full-Cycle Technologies from Organoid Development to Disease Modeling
FDA Unveils Roadmap to Reduce Animal Testing and Pave the Way for Human Stem Cell-Based Technologies
NEXEL "Leading the Way in Establishing 'Innovative Research and Development and Testing Methods' with Human-Induced Pluripotent Stem Cells"
NEXEL and Johns Hopkins University's Microphysiological Systems Sign MOU for 'Stem Cell and Organoid Research'
NEXEL、日本DNPとヒト由来幹細胞心筋細胞の培養技術提携
NEXEL begins listing on KOSDAQ... Submission of request for preliminary evaluation
NEXEL Passes Technology Evaluation
BioHealth R&D Best Companies Awards
Nexel Announces Results of Cardiac Safety Pharmacology Research at the World Society of Safety Pharmacology
